All In Biotech

Drug Trial Radar · NCT07339748

A Clinical Study of ZL-85FA Tablets

An Open-label, Multicenter Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ZL-85FA Tablets in Treating Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter phase I/IIa clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZL-85FA tablets in treating advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 2.5mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 5mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 10mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 15mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 20mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 25mg, oral, once daily

  • ZL-85FA tabletsDrug

    ZL-85FA tablets 30mg, oral, once daily

  • ZL-85FA tabletsDrug

    Based on the results obtained from the dose escalation phase, the necessity and dosage of the IIa phase expansion cohort will be determined by the Drug Safety Review Committee (SMC) after discussion.

  • ZL-85FA tabletsDrug

    Based on the results obtained from the dose escalation phase, the necessity and dosage of the IIa phase expansion cohort will be determined by the Drug Safety Review Committee (SMC) after discussion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rateTime frame: Up to week 96

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.